Diamyd Medical (DMYD) Investing in Life Science 2025 summary

Mission and disease background

• Founded with the goal to cure Type 1 diabetes, driven by a personal connection to the disease.

• Type 1 diabetes remains a significant unmet medical need, with insulin as the mainstay for over a century but not a cure.

• Over 500,000 new diagnoses annually, with societal costs nearing $100 billion due to complications.

• Patients face lifelong insulin dependence and a much higher risk of complications, including cardiovascular disease and reduced lifespan.

Therapy development and clinical approach

• Developing a disease-modifying therapy (Diamyd) aimed at halting the autoimmune attack on insulin-producing cells.

• Therapy is antigen-specific, reprogramming the immune system to tolerate a key endogenous protein, resulting in a favorable safety profile.

• Over 1,000 patients treated with active substance and 600 with placebo, showing similar safety profiles and mostly mild injection site irritation.

• Precision medicine approach: efficacy depends on patients having the right genetic profile, now targeting the 40% of Type 1 diabetics who qualify.

Clinical trial progress and results

• Fast track designation in the U.S. for all disease stages and orphan drug status secured.

• Phase III trial is the only ongoing global study for a disease-modifying therapy in Type 1 diabetes, with patient selection based on genetics.

• Data shows about 50% preservation of insulin-producing capacity at 15 months compared to placebo, with potential for significant delay in disease progression.

• Early-stage data suggests up to a seven-year delay to clinical diagnosis for some patients.

• Phase III trial is pivotal, with a single trial sufficient for regulatory approval, and an early readout expected March-April next year.